| Literature DB >> 19364361 |
A C Ludolph1, J Kassubek, B G Landwehrmeyer, E Mandelkow, E-M Mandelkow, D J Burn, D Caparros-Lefebvre, K A Frey, J G de Yebenes, T Gasser, P Heutink, G Höglinger, Z Jamrozik, K A Jellinger, A Kazantsev, H Kretzschmar, A E Lang, I Litvan, J J Lucas, P L McGeer, S Melquist, W Oertel, M Otto, D Paviour, T Reum, A Saint-Raymond, J C Steele, M Tolnay, H Tumani, J C van Swieten, M T Vanier, J-P Vonsattel, S Wagner, Z K Wszolek.
Abstract
Tauopathies with parkinsonism represent a spectrum of disease entities unified by the pathologic accumulation of hyperphosphorylated tau protein fragments within the central nervous system. These pathologic characteristics suggest shared pathogenetic pathways and possible molecular targets for disease-modifying therapeutic interventions. Natural history studies, for instance, in progressive supranuclear palsy, frontotemporal dementia with parkinsonism linked to chromosome 17, corticobasal degeneration, and Niemann-Pick disease type C as well as in amyotrophic lateral sclerosis/Parkinson-dementia complex permit clinical characterization of the disease phenotypes and are crucial to the development and validation of biological markers for differential diagnostics and disease monitoring, for example, by use of neuroimaging or proteomic approaches. The wide pathologic and clinical spectrum of the tauopathies with parkinsonism is reviewed in this article, and perspectives on future advances in the understanding of the pathogenesis are given, together with potential therapeutic strategies.Entities:
Mesh：
Substances：
Year: 2009 PMID： 19364361 PMCID： PMC2847416 DOI： 10.1111/j.1468-1331.2008.02513.x
Source DB: PubMed Journal: Eur J Neurol ISSN： 1351-5101 Impact factor: 6.089